Tian Zhang, MD, UT Southwestern Medical Center, Dallas, TX, discusses findings from the Phase II STARTAR trial (NCT03311555) of androgen receptor inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy followed by docetaxel in patients with PSA recurrent prostate cancer. 3-year progression-free survival was increased after treatment, demonstrating the clinical feasibility of intensifying systemic treatments for PSA recurrent prostate cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.